Benson et al. Clinical features that predict CV risk in PsA. Median 3.53 year follow up. 56 CV events. 766 patients. Dactylitis emerged as key predictor in adjusted models. @RheumNow #ACR25 Abstr#2317 https://t.co/5O3G7vGYbq

• https://x.com/RichardPAConway/status/1983205114946183664/photo/1

Cutaneous vasculitis: who is most likely to have systemic disease? 430 pt w skin vasculitis examined in case-control Associated with risk for systemic vasculitis/CTD: - GI sx - ulcerating/necrotic lesions - constitutional sx - hematuria @RheumNow #ACR25 Abst 2525 https://t.co/lRjLKRYxDW

• https://x.com/Dr_Brian_MD/status/1983204033729892687/photo/1

How great would it be to have a diagnostic RA-ILD Urine Dipstick? Small cohort 14 RA-ILD vs. 64 RA no ILD Urine ILDScore includes 2 proteins SPOCK1 and PGRMC1 Independently asso with ILD w/ OR 6.19 Urine ILD score alone AUC 0.9 ILD urine score + clinical data AUC = 0.95 Needs https://t.co/7PqX8kdjKJ

• https://x.com/AurelieRheumo/status/1983204030143713324/photo/1
• https://x.com/AurelieRheumo/status/1983204030143713324/photo/1

To be continued (or discontinued?): Abstract 2360: Compared to TNFi, IL-17i & JAKi users had 🔹 Higher odds of med switching <180 days 🔹 Shorter time to discontinuation @RheumNow #ACR25 #axSpA https://t.co/IOHaFSJqHn

• https://x.com/AkhilSoodMD/status/1983203353975808401/photo/1

Interesting study evaluating the "CALLY" index (serum albumin × lymphocyte count / CRP / 10,000) for predicing mortality in AAV I typically dislike these because (1) they are often cumbersome to calculate & (2) they often perform poorly This one piqued my interest; pretty https://t.co/ziroQOH5Cq

• https://x.com/EBRheum/status/1983203214729085107/photo/1

Meta-analysis of 3 RCTs (n=1990) shows IL-17i offers comparable joint response but superior skin clearance vs adalimumab in biologic-naive PsA. IL-17i also had fewer discontinuations due to adverse events. Supports sequencing of biologics through different mechanisms of action in https://t.co/SJgFUMxWVb

• https://x.com/synovialjoints/status/1983202097903370743/photo/1

IgG4-RD continues to present in new and unusual ways Hasbani et al. report 9 IgG4-RD patients with coronary artery involvement RCA and LAD most affected Seen on CTA Majority received RTX 7/9 pt at least partially improved imaging on f/u @RheumNow #ACR25 Abst 2531 https://t.co/Na0gdq3dgb

• https://x.com/Dr_Brian_MD/status/1983201652707602640/photo/1

A new genetic score for ILD prediction! 🫁 Developed in the Veterans RA cohort and Validation in a Swedish cohort Model using classic RA-ILD risk factors and a cocktail of genetic risk A cut off of 0.05 in this cohort would exclude 36% from HRCT or PFTs Good performance https://t.co/6UsoSQAtyK

• https://x.com/AurelieRheumo/status/1983201641340747804/photo/1
• https://x.com/AurelieRheumo/status/1983201641340747804/photo/1

RESET-RA, RCT of vagus nerve stim (device that zaps pts in neck) Marginal improvements in ACR20 at wk 12; trend in to improvement in unblinded part of study fwiw Have never seen result that is more likely to be driven by plbo effect & unblinding 🤪 @RheumNow #ACR25 Abstr#2278 https://t.co/BlR570nv7k

• https://x.com/EBRheum/status/1983201340403704312/photo/1
• https://x.com/EBRheum/status/1983201340403704312/photo/1
• https://x.com/EBRheum/status/1983201340403704312/photo/1
• https://x.com/EBRheum/status/1983201340403704312/photo/1

Hindosh et al. Semaglutide associated with reduced synovitis, joint pain and swelling, in RA. @RheumNow #ACR25 Abstr#2286 https://t.co/6Xs4um5l32

• https://x.com/RichardPAConway/status/1983201088410136955/photo/1

MSK side effects of CAR-T, based on FAERS pharmacovigilance data (also see @DrGomezPuerta in @seminarthrheum https://t.co/LnwjU5aebs) #ACR25 ABST1731 @RheumNow https://t.co/kREEy3HLE9

• https://www.sciencedirect.com/science/article/abs/pii/S0049017224002506
• https://x.com/drdavidliew/status/1983201000443072522/photo/1

Late Breaker: Observational study of MEPO in EGPA 375 pts receiving MEPO had less ARF/CKD than 727 pts receiving standard of care Smallish event #'s & lots of p values... also, what about the vasculitis?!? #ACR25 @RheumNow AbstLB16 https://t.co/XwqNthfwPF

• https://x.com/EBRheum/status/1983200585374380336/photo/1
• https://x.com/EBRheum/status/1983200585374380336/photo/1

Bremer et al. Earlier initiation of biosimilar adalimumab (vs csDMARDs) may result in cost-savings. Reduced cost of tests, consultations, and hospitalisations. @RheumNow #ACR25 Abstr#2271 https://t.co/lHaSiX3WLd

• https://x.com/RichardPAConway/status/1983200333644902456/photo/1

Semaglutide isn’t just for weight loss? In RA, users had 20–40% lower risk of synovitis, stiffness & swelling up to 1 year vs matched controls. GLP-1 agonists may offer anti-inflammatory benefit beyond metabolism. @RheumNow #ACR25 Abstract#2286

PLEX continues to be OUT for DAH in AAV Retrospective review of ~1.4k AAV-DAH pt 375 who received PLEX compared to those who did not PLEX tx patients: - higher odds of death - higher sepsis - increased LOS - increased hospitalization cost @RheumNow #ACR25 Abst 2517